Combivent

(Redirected from Ipratropium/salbutamol)
Jump to: navigation, search

WikiDoc Resources for Combivent

Articles

Most recent articles on Combivent

Most cited articles on Combivent

Review articles on Combivent

Articles on Combivent in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Combivent

Images of Combivent

Photos of Combivent

Podcasts & MP3s on Combivent

Videos on Combivent

Evidence Based Medicine

Cochrane Collaboration on Combivent

Bandolier on Combivent

TRIP on Combivent

Clinical Trials

Ongoing Trials on Combivent at Clinical Trials.gov

Trial results on Combivent

Clinical Trials on Combivent at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Combivent

NICE Guidance on Combivent

NHS PRODIGY Guidance

FDA on Combivent

CDC on Combivent

Books

Books on Combivent

News

Combivent in the news

Be alerted to news on Combivent

News trends on Combivent

Commentary

Blogs on Combivent

Definitions

Definitions of Combivent

Patient Resources / Community

Patient resources on Combivent

Discussion groups on Combivent

Patient Handouts on Combivent

Directions to Hospitals Treating Combivent

Risk calculators and risk factors for Combivent

Healthcare Provider Resources

Symptoms of Combivent

Causes & Risk Factors for Combivent

Diagnostic studies for Combivent

Treatment of Combivent

Continuing Medical Education (CME)

CME Programs on Combivent

International

Combivent en Espanol

Combivent en Francais

Business

Combivent in the Marketplace

Patents on Combivent

Experimental / Informatics

List of terms related to Combivent

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Synonyms / Brand Names: Ipratropium Bromide + Salbutamol Sulfate, Ipratropium/Salbutamol, Combivent Inhalation Aerosol, Combivent Inhalation Solution

Dosing and Administration

The dose of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol is two inhalations four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed 12 in 24 hours. Safety and efficacy of additional doses of Combivent Inhalation Aerosol beyond 12 puffs/24 hours have not been studied. Also, safety and efficacy of extra doses of ipratropium or albuterol in addition to the recommended doses of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol have not been studied. It is recommended to “test-spray” three times before using for the first time and in cases where the aerosol has not been used for more than 24 hours. Avoid spraying into eyes.


Adapted from the FDA Package Insert.



Linked-in.jpg